Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of liraglutide on pancreatic hormones and its size.

Next Previous
Trial Profile

The effect of liraglutide on pancreatic hormones and its size.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Acronyms LIRAP

Most Recent Events

  • 25 Sep 2020 Primary endpoint (Volumetric Changes of the Pancreas) has not been met as per results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes.
  • 25 Sep 2020 Results assessing Effects of a six-week intervention with glucagon like peptide 1 receptor analogue on pancreatic volume, oedema and DNA synthesis in obese men, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
  • 23 Mar 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top